Health ❯ Obesity

Treatment

Medications Pharmaceuticals Pharmacology Clinical Trials Pharmacotherapy GLP-1 Therapies Wegovy Chronic Disease Investigational Drugs Individualized Approaches

DNA Links Found for Who Loses Weight and Who Gets Sick on GLP-1 Drugs

The results point to future tailoring of care rather than an immediate shift in prescribing.

Study Finds Weight Rebounds Within Two Years After Stopping GLP-1 Drugs

Oxford Review Finds Rapid Weight Regain After Stopping GLP-1 Drugs

FDA Approves First Wegovy Pill for Chronic Weight Management

Brazil Cracks Down on Illicit Mounjaro Sales as Lilly Launches QR Verification Tool

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering

WHO Issues First Guideline Backing GLP-1 Drugs for Obesity With Conditional Use

WHO Issues First Global Guidance Backing Long‑Term GLP‑1 Therapy for Obesity

WHO Backs Long-Term GLP-1 Use for Obesity in First Global Guideline

WHO Endorses GLP‑1s for Obesity as Australia Adds Class‑Wide Mental Health Warning

Wegovy Launches in Argentina With Adolescent Indication and Proven Cardiovascular Benefit

GLP-1 Drugs Tied to Slower Alcohol Absorption and Weaker Intoxication in Virginia Tech Pilot

Wegovy Weight-Loss Injection Launches in Argentina With Published Prices, Prescription-Only Access

Novo Nordisk Taps Eurofarma to Launch Two Weekly Semaglutide Brands in Brazil

Phase 3 Trials Show Greater Weight Loss With 7.2 mg Injection and 25 mg Oral Semaglutide

Tufts Team Designs Experimental Four-Hormone Obesity Drug Aimed at Bigger, Gentler Weight Loss

Canada Overhauls Adult Obesity Pharmacotherapy Guidelines to Personalize Treatment

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Real-World GLP-1 Therapy Yields Lower Weight Loss, Spurs Tetra-Receptor Drug Research

Obesity Disrupts Olfactory Pathway That Reduces Hunger in Mice